Back to search

Article

¿p#1 Multidomain Clinical and Biological Remission with Tezepelumab in Severe Asthma: A 12-Month Multicentre Real-World Study

2025-11-17

Abstract excerpt

¿p#1 Background: Tezepelumab, an anti–thymic stromal lymphopoietin (TSLP) monoclonal antibody, has shown broad efficacy across severe asthma phenotypes. However, real-world evidence addressing multidomain remission, particularly with rigorous lung function criteria and detailed phenotypic characterisation, remains limited. <h4>Methods:</h4> This prospective multicentre study was conducted across 14 specialised ast...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cf849499-4de1-5832-8f52-cdb690a52353
DOI
10.22541/au.176339535.59158541/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
¿p#1 Multidomain Clinical and Biological Remission with Tezepelumab in Severe Asthma: A 12-Month Multicentre Real-World StudyDOI 10.22541/au.176339535.59158541/v1
Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted ApproachSemantic proximity
Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity
Beyond the Inhaler: How Biologics, Phenotyping, and the Pursuit of Remission Are Redefining Airway Disease.Semantic proximity
Biologics in severe asthma: from precision phenotyping to clinical remission.Semantic proximity
Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement.Semantic proximity
Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbiditiesSemantic proximity
Choice of biologics in asthma endotypes.Semantic proximity
Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity
Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype.Semantic proximity
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis.Semantic proximity
Choosing the right biologic treatment for individual patients with severe asthma - Lessons learnt from Picasso.Semantic proximity
Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient.Semantic proximity
Select a neighboring publication to make it the new centre.